WHO Drug Information Vol. 14, No. 1, 2000
(2000; 81 pages) Voir le document au format PDF
Table des matières
Ouvrir ce répertoire et afficher son contenuGeneral Policy Issues
Ouvrir ce répertoire et afficher son contenuPersonal Perspectives
Ouvrir ce répertoire et afficher son contenuReports on Individual Drugs
Ouvrir ce répertoire et afficher son contenuCurrent Topics
Ouvrir ce répertoire et afficher son contenuVaccines and Biomedicines
Ouvrir ce répertoire et afficher son contenuGeneral Information
Fermer ce répertoireRegulatory and Safety Matters
Afficher le documentTroglitazone withdrawn
Afficher le documentCisapride and cardiac effects
Afficher le documentCisapride: changes to labelling
Afficher le documentCisapride: updated warning issued
Afficher le documentSt John's wort: recommendations for use
Afficher le documentNorthern hemisphere influenza vaccine
Afficher le documentNicotine replacement therapy
Afficher le documentAnorectic agents: suspension of marketing authorization
Afficher le documentInsulin cartridges: leakage risk
Afficher le documentZimox®: trade name duplication and risk of errors
Afficher le documentBenzbromarone and hepatitis
Afficher le documentNevirapine: severe cutaneous reactions
Afficher le documentFDA cannot regulate tobacco industry
Afficher le documentNew Internet website: information for consumers
Afficher le documentCyber warnings for drug sales via the Internet
Afficher le documentTriax®: a harmful product sold on the Internet
Afficher le documentIllegal products on the market
Afficher le documentEpoetin alfa: inappropriate practices compromise product sterility
Afficher le documentPropylene glycol and amprenavir
Afficher le documentTrastuzumab: pulmonary reactions
Ouvrir ce répertoire et afficher son contenuATC/DDD Classification
Ouvrir ce répertoire et afficher son contenuRecent Publications and Documents
Ouvrir ce répertoire et afficher son contenuInternational Nonproprietary Names for Pharmaceutical Substances (INN)
Afficher le documentSelected WHO Publications of Related Interest
 

Northern hemisphere influenza vaccine

World Health Organization - The composition of the vaccine for the November 2000-April 2001 influenza season in the Northern hemisphere has been determined and communicated to vaccine manufacturers.

• an A/Moscow/10/99(H3N2)-like virus
• an A/New Caledonia/20/99(H1N1)-like virus
• a B/Beijing/184/93-like virus+

WHO strongly recommends the use of vaccine as an effective preventive measure against this potentially fatal disease. Even in those cases when the vaccine does not fully protect against the disease, severity of illness and frequency of serious complications are reduced.

Specific vaccine viruses used in each country should be approved by the national control authorities. National public health authorities are responsible for recommendations regarding use of vaccines. All WHO recommendations are published and communicated to public health authorities, national control authorities and influenza vaccine manufacturers. Updated epidemiological information is available on http://www.who.ch/emc/flu/index.htm and the geographical information system, Flunet, at http://oms.b3e.juu.fr/flunet.

Reference: Recommended composition of influenza virus vaccines for use in the 2000-2001 season. Weekly Epidemiological Record, 75: 61-65 (2000).

vers la section précédente vers la section suivante
 

Dernière mise à jour: le 3 mai 2013